Found: 124
Select item for more details and to access through your institution.
Eribulin Monotherapy in Patients Aged 70 Years and Older With Metastatic Breast Cancer.
- Published in:
- Oncologist, 2014, v. 19, n. 4, p. 318, doi. 10.1634/theoncologist.2013-0282
- By:
- Publication type:
- Article
Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Cardiac Toxicity of Trastuzumab-Related Regimens in HER2-Overexpressing Breast Cancer.
- Published in:
- Clinical Cancer Update, 2007, v. 1, n. 1, p. 22, doi. 10.3816/CCU.2007.n.004
- By:
- Publication type:
- Article
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
- Published in:
- BMC Cancer, 2014, v. 14, p. 1, doi. 10.1186/1471-2407-14-307
- By:
- Publication type:
- Article
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
- Published in:
- BMC Cancer, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1471-2407-14-307
- By:
- Publication type:
- Article
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Targeted Therapy Options for HER2+ Breast Cancer.
- Published in:
- Oncology (08909091), 2024, v. 38, p. 12
- By:
- Publication type:
- Article
Multidisciplinary Care Is Imperative to the Future of Breast Cancer Treatment.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 5, p. 202
- By:
- Publication type:
- Article
Advancing the Field of Breast Cancer Care: A "sea change" in treatment.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 4, p. 130
- By:
- Publication type:
- Article
De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
- Published in:
- Oncologist, 2020, v. 25, n. 2, p. e214, doi. 10.1634/theoncologist.2019-0446
- By:
- Publication type:
- Article
Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus‐Associated Stomatitis: A Randomized Phase II Study.
- Published in:
- Oncologist, 2019, v. 24, n. 9, p. 1153, doi. 10.1634/theoncologist.2018-0340
- By:
- Publication type:
- Article
Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel.
- Published in:
- Biomarker Research, 2023, v. 11, n. 1, p. 1, doi. 10.1186/s40364-023-00511-7
- By:
- Publication type:
- Article
Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 1998, v. 5, n. 2, p. 150, doi. 10.1007/BF02303848
- By:
- Publication type:
- Article
Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer
- Published in:
- Quality of Life Research, 2012, v. 21, n. 5, p. 765, doi. 10.1007/s11136-011-9999-z
- By:
- Publication type:
- Article
Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2− breast cancer.
- Published in:
- Breast Journal, 2019, v. 25, n. 5, p. 880, doi. 10.1111/tbj.13345
- By:
- Publication type:
- Article
Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
- Published in:
- NPJ Breast Cancer, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41523-024-00639-1
- By:
- Publication type:
- Article
Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00490-2
- By:
- Publication type:
- Article
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00467-1
- By:
- Publication type:
- Article
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00439-5
- By:
- Publication type:
- Article
Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2011, v. 103, n. 3, p. 264, doi. 10.1093/jnci/djq524
- By:
- Publication type:
- Article
Chemoprevention of breast cancer.
- Published in:
- JAMA: Journal of the American Medical Association, 1996, v. 275, n. 17, p. 1349, doi. 10.1001/jama.1996.03530410063035
- By:
- Publication type:
- Article
Dose-intensive therapy for breast cancer.
- Published in:
- JAMA: Journal of the American Medical Association, 1993, v. 270, n. 17, p. 2089, doi. 10.1001/jama.1993.03510170079035
- By:
- Publication type:
- Article
Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231152843
- By:
- Publication type:
- Article
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221083956
- By:
- Publication type:
- Article
"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
- Published in:
- Breast Cancer Research, 2015, v. 17, n. 1, p. 1, doi. 10.1186/s13058-015-0568-1
- By:
- Publication type:
- Article
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Capecitabine plus docetaxel combination therapyF. Hoffmann‐La Roche Ltd. supported the development of the model and the subsequent analyses. The sponsor had no role in the model design, cost‐effectiveness analysis, or interpretation of the results. All investigators had unlimited access to the model and data. No limitations on publication were imposed. The authors made the final decisions on all aspects of the current article.: Cost‐effectiveness in patients with anthracycline‐pretreated advanced breast carcinoma
- Published in:
- Cancer (0008543X), 2005, v. 103, n. 12, p. 2455
- By:
- Publication type:
- Article
Ductal lavage and the clinical management of women at high risk for breast carcinoma.
- Published in:
- Cancer (0008543X), 2002, v. 94, n. 2, p. 292, doi. 10.1002/cncr.10238
- By:
- Publication type:
- Article
Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 3, p. 1153, doi. 10.1007/s12325-022-02365-1
- By:
- Publication type:
- Article
Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11293-4
- By:
- Publication type:
- Article
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 170, n. 3, p. 535, doi. 10.1007/s10549-018-4769-z
- By:
- Publication type:
- Article
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 170, n. 3, p. 547, doi. 10.1007/s10549-018-4770-6
- By:
- Publication type:
- Article
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 168, n. 1, p. 127, doi. 10.1007/s10549-017-4518-8
- By:
- Publication type:
- Article
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
- Published in:
- 2017
- By:
- Publication type:
- Erratum
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
- Published in:
- Breast Cancer Research & Treatment, 2017, v. 165, n. 2, p. 329, doi. 10.1007/s10549-017-4304-7
- By:
- Publication type:
- Article
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 154, n. 1, p. 89, doi. 10.1007/s10549-015-3599-5
- By:
- Publication type:
- Article
Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples.
- Published in:
- Breast Cancer Research & Treatment, 2014, v. 148, n. 2, p. 315, doi. 10.1007/s10549-014-3163-8
- By:
- Publication type:
- Article
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2014, v. 146, n. 2, p. 321, doi. 10.1007/s10549-014-2923-9
- By:
- Publication type:
- Article
Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
- Published in:
- 2014
- By:
- Publication type:
- Erratum
Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients.
- Published in:
- Breast Cancer Research & Treatment, 2013, v. 142, n. 2, p. 381, doi. 10.1007/s10549-013-2742-4
- By:
- Publication type:
- Article
A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2013, v. 139, n. 1, p. 107, doi. 10.1007/s10549-013-2510-5
- By:
- Publication type:
- Article
nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis.
- Published in:
- Breast Cancer Research & Treatment, 2013, v. 138, n. 3, p. 829, doi. 10.1007/s10549-013-2447-8
- By:
- Publication type:
- Article
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.
- Published in:
- Breast Cancer Research & Treatment, 2012, v. 134, n. 1, p. 333, doi. 10.1007/s10549-012-2035-3
- By:
- Publication type:
- Article
Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2011, v. 126, n. 1, p. 101, doi. 10.1007/s10549-010-1286-0
- By:
- Publication type:
- Article
Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study.
- Published in:
- Breast Cancer Research & Treatment, 2011, v. 125, n. 1, p. 115, doi. 10.1007/s10549-010-1187-2
- By:
- Publication type:
- Article
Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2010, v. 118, n. 2, p. 361, doi. 10.1007/s10549-009-0410-5
- By:
- Publication type:
- Article
The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2009, v. 116, n. 3, p. 521, doi. 10.1007/s10549-008-0284-y
- By:
- Publication type:
- Article
A decade of letrozole: FACE.
- Published in:
- 2008
- By:
- Publication type:
- Correction notice